KR960010683A - 소마토스타틴 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물 - Google Patents

소마토스타틴 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR960010683A
KR960010683A KR1019950028905A KR19950028905A KR960010683A KR 960010683 A KR960010683 A KR 960010683A KR 1019950028905 A KR1019950028905 A KR 1019950028905A KR 19950028905 A KR19950028905 A KR 19950028905A KR 960010683 A KR960010683 A KR 960010683A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
radionuclide
complex
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950028905A
Other languages
English (en)
Other versions
KR100364111B1 (ko
Inventor
알버트 라이너
브룬스 크리스티안
스미스-존즈 페터
스톨츠 바바라
베크베커 기스버트
Original Assignee
페. 래스·에이치. 알. 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페. 래스·에이치. 알. 하우스, 산도즈 리미티드 filed Critical 페. 래스·에이치. 알. 하우스
Publication of KR960010683A publication Critical patent/KR960010683A/ko
Application granted granted Critical
Publication of KR100364111B1 publication Critical patent/KR100364111B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

유리 형태 또는 염 형태인 하기 일반식(Ⅰ)의 화합물은 α선-또는 β선-방출 방사성핵종 또는 오오제-전자-캐스캐이드를 가지는 핵종과 착화합물을 형성했을때 방사성 의약품으로서 유용하다.
상기 식에서, M은 양이온 등가물이고, A는 페닐알라닌 또는 타이로신이다.

Description

소마토스타딘 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 유리 형태, 염 형태 또는 방사성 핵종과 착화합된 형태의 일반식(Ⅰ)의 화합물.
    상기 식에서, M은 양이온이고, A는 페닐알라닌 또는 타이로신이다.
  2. 제1항에 있어서, A가 타이로신인 화합물.
  3. 제1항에 또는 제2항에 있어서,90Y또는161Tb와 착화합물을 형성한 화합물.
  4. 제1항에 있어서,M이 H+인 화합물.
  5. 방사성핵종과 착화합물을 형성한 제1항의 일반식 (Ⅰ)의 화합, 또는 그 약학적 허용염을 포함하고, 하나 이상의 약학적 허용 담체 및 회석제를 포함하는 소마토스타틴 수용테 양성인 종양 및 그 전이부 치료용 약학조성물.
  6. 제5 항에 있어서, 부가적으로 안정화제를 포함하는 약학 조성물.
  7. 제6항에 있어서, 안정화제가 혈청 알부민, 아스코르빈산, 레티놀, 겐티신산 또는 그 유도체, 및 아미노산 용액으로 이루어진 그룹중에서 선택되는 특징으로 하는 약학 조성물.
  8. 60내지 120℃의 온도에서 방사성핵종-산출 화합물과 일ㄹ반식(Ⅰ)의 화합물을 반응시키는 단계로 구성되는 제1항의 일반식(Ⅰ)이 화합물과 방사성핵종을 착화합시키는 방법.
  9. 방사성핵종과 착화합물을 형성한 일반식(Ⅰ)의 화합물, 또는 그 약학적 허용염을 포함하는 약학 조성물을 함유하면서 추가로 세포증식 억제제를 포함하는 하나 이상의 약학 조성물을 함유하는 종양 침윤성 및 종양 성장과 관련된 증후군 치료용 조합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950028905A 1994-09-06 1995-09-05 소마토스타틴펩타이드,이의제법및이를함유하는약학적조성물 Expired - Lifetime KR100364111B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417873A GB9417873D0 (en) 1994-09-06 1994-09-06 Organic compounds
GB9417873.8 1994-09-06

Publications (2)

Publication Number Publication Date
KR960010683A true KR960010683A (ko) 1996-04-20
KR100364111B1 KR100364111B1 (ko) 2003-02-05

Family

ID=10760870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950028905A Expired - Lifetime KR100364111B1 (ko) 1994-09-06 1995-09-05 소마토스타틴펩타이드,이의제법및이를함유하는약학적조성물

Country Status (31)

Country Link
US (2) US6183721B1 (ko)
EP (1) EP0714911B1 (ko)
JP (1) JP3054346B2 (ko)
KR (1) KR100364111B1 (ko)
CN (1) CN1185252C (ko)
AT (1) ATE199561T1 (ko)
AU (1) AU703057B2 (ko)
BR (1) BR9503936A (ko)
CA (1) CA2157530C (ko)
CO (1) CO4410344A1 (ko)
CZ (1) CZ287012B6 (ko)
DE (1) DE69520256T2 (ko)
DK (1) DK0714911T3 (ko)
ES (1) ES2157309T3 (ko)
FI (1) FI117424B (ko)
GB (1) GB9417873D0 (ko)
GR (1) GR3035997T3 (ko)
HU (1) HU218284B (ko)
IL (1) IL115154A (ko)
NO (1) NO316569B1 (ko)
NZ (1) NZ272919A (ko)
PE (1) PE41496A1 (ko)
PL (1) PL182434B1 (ko)
PT (1) PT714911E (ko)
RU (1) RU2156774C2 (ko)
SG (1) SG50356A1 (ko)
SI (1) SI0714911T1 (ko)
SK (1) SK283774B6 (ko)
TR (1) TR199501094A2 (ko)
TW (1) TW387898B (ko)
ZA (1) ZA957475B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
BR0207315A (pt) * 2001-02-26 2004-02-10 Bristol Myers Squibb Pharma Co Análogos de ácido ascórbico para metalorradiofármacos
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
US7211250B2 (en) 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
JP2006522100A (ja) * 2003-03-10 2006-09-28 バイオジェン アイデック インク 標的化ペプチドに対するチオール媒介性薬物結合
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20100029911A1 (en) * 2004-11-24 2010-02-04 Aplagen Gmbh Method For Solid-Phase Peptide Synthesis And Purification
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20140170068A1 (en) 2011-03-11 2014-06-19 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
EP2922578B1 (en) 2012-11-21 2018-12-12 Serene, Llc Tin-117m comprising somatostatin receptor binding compounds
CN103275189B (zh) * 2013-06-06 2014-08-06 深圳翰宇药业股份有限公司 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3383920B1 (en) 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US11235076B2 (en) 2016-08-29 2022-02-01 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CA3050094C (en) 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
TW202015744A (zh) * 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202547563A (zh) * 2018-06-21 2025-12-16 德商愛利穆治療有限公司 用於放射性醫藥之含有體抑素類似物之組成物
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US20200030466A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
JPWO2025058000A1 (ko) 2023-09-13 2025-03-20

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US5006643A (en) 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
DE3728600A1 (de) 1987-08-27 1989-03-09 Hoechst Ag Verfahren zur markierung von substanzen mit technetium oder rhenium
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
WO1991004755A1 (en) 1989-09-29 1991-04-18 Neorx Corporation Methods for reducing non-target retention of immunoconjugates and metabolites thereof
JPH07505621A (ja) * 1992-03-25 1995-06-22 マリンクロッド・インコーポレイテッド 外科手術中における腫瘍組織の検出および探知法
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
NO940080L (no) * 1993-01-12 1994-07-13 Sandoz Ag Polypeptider , fremgangsmåte for deres fremstilling og farmasöytiske preparater derav
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
TW387898B (en) 2000-04-21
NO953457L (no) 1996-03-07
DE69520256D1 (de) 2001-04-12
ATE199561T1 (de) 2001-03-15
PE41496A1 (es) 1996-10-14
PL182434B1 (pl) 2002-01-31
FI117424B (fi) 2006-10-13
SK108895A3 (en) 1996-06-05
JP3054346B2 (ja) 2000-06-19
FI954147A0 (fi) 1995-09-04
DK0714911T3 (da) 2001-07-09
DE69520256T2 (de) 2001-08-09
HUT72895A (en) 1996-06-28
NO316569B1 (no) 2004-02-23
AU3041495A (en) 1996-03-21
GB9417873D0 (en) 1994-10-26
US6277356B1 (en) 2001-08-21
CZ287012B6 (en) 2000-08-16
FI954147L (fi) 1996-03-07
ZA957475B (en) 1997-03-06
ES2157309T3 (es) 2001-08-16
EP0714911A2 (en) 1996-06-05
NO953457D0 (no) 1995-09-04
HU218284B (en) 2000-07-28
GR3035997T3 (en) 2001-09-28
CN1185252C (zh) 2005-01-19
CN1127259A (zh) 1996-07-24
PT714911E (pt) 2001-08-30
SI0714911T1 (en) 2001-08-31
TR199501094A2 (tr) 1996-06-21
SK283774B6 (sk) 2004-01-08
RU2156774C2 (ru) 2000-09-27
HU9502577D0 (en) 1995-11-28
SG50356A1 (en) 2000-11-21
CZ226395A3 (en) 1996-03-13
EP0714911B1 (en) 2001-03-07
US6183721B1 (en) 2001-02-06
KR100364111B1 (ko) 2003-02-05
NZ272919A (en) 1996-12-20
CA2157530C (en) 2007-04-03
AU703057B2 (en) 1999-03-11
PL310274A1 (en) 1996-03-18
EP0714911A3 (en) 1996-08-21
CO4410344A1 (es) 1997-01-09
CA2157530A1 (en) 1996-03-07
BR9503936A (pt) 1996-09-24
IL115154A (en) 2000-08-13
IL115154A0 (en) 1995-12-31
JPH0881498A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
AU546390B2 (en) Polishing composition
RU95114740A (ru) Пептиды
GB1506640A (en) Salts of s-adenosyl-l-methionine
Yeh et al. Decomposition rates of radiopharmaceutical indium chelates in serum
KR920007639A (ko) 방사능의약품 조성물의 제조방법
Benisek et al. Attachment of Metal-chelating Functional Groups to Hen Egg White Lysozyme: AN APPROACH TO INTRODUCING HEAVY ATOMS INTO PROTEIN CRYSTALS
GB1433828A (en) Molecular inclusion compounds
Leung et al. The attachment of metal-chelating groups to proteins: Tagging of albumin by diazonium coupling and use of the products as radiopharmaceuticals
Hulla et al. Synthesis of an adenosine 5'-monophosphate analog and its use for the affinity labeling of the effector binding site of rabbit skeletal muscle phosphorylase b
PT76782B (en) Process for preparing novel substituted (+)-cyanidan-3-ol derivatives
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
KR830007092A (ko) 방사성 진단제 및 그의 비-방사성 담체
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
GB1493684A (en) S-substituted-2-thiodenosines
GB1182815A (en) New Salts of N-Carbamyl-Glutamic Acid and of N-Carbamyl-Aspartic Acid.
GB1243953A (en) Benzdiazepine derivatives
SE7609979L (sv) Forfaringssett for framstellning av tverbunden orgotein
Lien et al. The mechanism of cobalamin binding to hog intrinsic factor
KR840005107A (ko) 피리미디온 및 그의 산부가염의 제조방법
GB1449426A (en) Phenoxyalkylamine derivatives and preparation therof
Henderson et al. Irreversible inhibition of folate transport in Lactobacillus casei by covalent modification of the binding protein with carbodiimide-activated folate
GB1290381A (ko)
GB1449078A (en) Phenoxyethylamine derivatives
GB1475114A (en) 4-amino-3-hydrazino-1,2,4-triazole derivatives methods for their preparation and compositions containing them
Ratti et al. Configuration of the asparaginyl and aspartyl residues of bacitracin

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19950905

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19980312

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20000901

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19950905

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20020827

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20021127

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20021128

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20050926

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20061124

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20071123

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20081126

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20091123

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20101125

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20111101

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20121031

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20131101

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20131101

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20141107

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20141107

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term